読み込み中
NASDAQHealthcareBiotechnology
最新データ
$0.9654
−$0.0071 · -0.73%
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
前日終値
$0.9654
−$0.0071 · -0.73%
日中の時刻はETです。市場データは遅延する場合があります。
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
日中レンジ
現在 $0.9654
52週レンジ
現在 $0.9654
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
49
適正価値
センチメント
55
まちまち
リスク
85
極めて高いリスク
モメンタム
27
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
日中レンジ
現在 $0.9654
52週レンジ
現在 $0.9654
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 100.55万 USD | 60.76万 USD | 25.36万 USD | 22.32万 USD | 116.03万 USD |
| 売上原価 | 78.17万 USD | 38.48万 USD | 47.46万 USD | 43.24万 USD | 85.07万 USD |
| 粗利益 | 22.38万 USD | 22.28万 USD | −22.1万 USD | −20.92万 USD | 30.96万 USD |
| 研究開発 | 210.62万 USD | 498.65万 USD | 69.18万 USD | 52.56万 USD | 551.09万 USD |
| 販売・一般管理 | 627.98万 USD | 502.5万 USD | 424.18万 USD | 130.37万 USD | 111.54万 USD |
| 営業費用 | 798.24万 USD | 993.77万 USD | 493.36万 USD | 154.13万 USD | 143.37万 USD |
| 支払利息 | 7805 USD | 7912 USD | 228.66万 USD | 398.94万 USD | 317.27万 USD |
| 減価償却費と償却費 | 8.29万 USD | 6.37万 USD | 10.04万 USD | 7.88万 USD | 7.18万 USD |
| 営業利益 | −775.86万 USD | −971.49万 USD | −515.46万 USD | −175.04万 USD | −112.41万 USD |
| 純利益 | −736.83万 USD | −794.71万 USD | −376.57万 USD | −618.17万 USD | −425.17万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年1月20日 | 1:4 | — | — |
株式分割 | 2025年2月24日 | 1:5 | — | — |
株式分割 | 2024年8月12日 | 1:12 | — | — |
発効済み 2026年1月20日
1:4
発効済み 2025年2月24日
1:5
発効済み 2024年8月12日
1:12
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
